ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
CRISPR Therapeutics AG

CRISPR Therapeutics AG (CRSP)

51.17
0.33
(0.65%)
마감 01 12월 6:00AM
51.18
0.01
(0.02%)
시간외 거래: 7:00AM

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

주요 통계 및 세부정보

가격
51.17
매수가
48.00
매도가
52.00
거래량
731,252
50.50 일간 변동폭 51.67
43.42 52주 범위 91.10
market_cap
전일 종가
50.84
개장가
51.04
최근 거래 시간
11
@
50.8
마지막 거래 시간
재정 규모
US$ 37,474,840
VWAP
51.2475
평균 볼륨(3m)
1,361,898
발행 주식
85,353,479
배당수익률
-
주가수익률
-28.43
주당순이익(EPS)
-1.8
매출
371.21M
순이익
-153.61M

CRISPR Therapeutics AG 정보

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specifi... CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
본부
Zug, Che
설립됨
-
CRISPR Therapeutics AG is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker CRSP. The last closing price for CRISPR Therapeutics was US$50.84. Over the last year, CRISPR Therapeutics shares have traded in a share price range of US$ 43.42 to US$ 91.10.

CRISPR Therapeutics currently has 85,353,479 shares in issue. The market capitalisation of CRISPR Therapeutics is US$4.34 billion. CRISPR Therapeutics has a price to earnings ratio (PE ratio) of -28.43.

CRISPR Therapeutics (CRSP) 옵션 플로우 요약

전체 흐름

약세

순 프리미엄

-61M

Calls / Puts

10.71%

매수 / 매도

45.00%

OTM / ITM

19.23%

Sweeps 비율

0.00%

CRSP 최신 뉴스

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...

CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

ZUG, Switzerland and BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

-CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
14.8210.399137001146.3551.727545.85148196249.26232041CS
44.218.9650766609946.9659.069345.51194770149.63170376CS
125.9213.082872928245.2559.069343.42136189848.40181545CS
26-2.51-4.6758569299653.6867.8843.42131372951.69780484CS
52-20.21-28.31325301271.3891.143.42167333860.75900075CS
156-28.63-35.877192982579.891.137.55149970059.99175342CS
260-17.02-24.959671506168.19220.2132142640178.71080327CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
BSLKBolt Projects Holdings Inc
US$ 0.71
(139.86%)
80.81M
PRZOParaZero Technologies Ltd
US$ 1.24
(94.14%)
205.02M
AIEVThunder Power Holdings Inc
US$ 0.47
(87.25%)
122.71M
PASGPassage Bio Inc
US$ 1.13
(69.52%)
15.44M
EPOWSunrise New Energy Company Ltd
US$ 1.06
(45.21%)
314.9k
APLTApplied Therapeutics Inc
US$ 2.03
(-76.31%)
43.9M
TGLTreasure Global Inc
US$ 0.2944
(-29.08%)
1.85M
PROCProcaps Group SA
US$ 1.51
(-27.75%)
106.08k
SHOTWSafety Shot Inc
US$ 0.104
(-20.00%)
1.43k
MONDMondee Holdings Inc
US$ 0.7102
(-19.59%)
297.63k
PRZOParaZero Technologies Ltd
US$ 1.24
(94.14%)
205.02M
NVDANVIDIA Corporation
US$ 138.25
(2.15%)
141.86M
AIEVThunder Power Holdings Inc
US$ 0.47
(87.25%)
122.71M
RGTIRigetti Computing Inc
US$ 3.05
(27.08%)
116.98M
MARAMARA Holdings Inc
US$ 27.42
(1.86%)
89.54M

CRSP Discussion

게시물 보기
jondoeuk jondoeuk 4 시간 전
CTX130 data in R/R T-cell lymphomas (peripheral T-cell lymphoma or cutaneous T-cell lymphoma) https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00508-4/abstract

The ORR was 46.2%. Of those treated at DL3 and higher, the ORR was 51.6%.
👍️0
PonkenPlonken PonkenPlonken 6 일 전
so so so undervalued and misunderstood i believe...... frankly just cheap
https://x.com/RNAiAnalyst/status/1859876294487363651
👍️ 1
jondoeuk jondoeuk 2 주 전
They now have the ability to put in eight to nine edits. So it is a single cassette that expresses the CAR, can express a cytokine and has an shRNA-like approach to knock down genes. So there's no theoretical limit as to the number of edits, but there may be marginal utility beyond a certain point.

Hopefully, they look to improve donor selection, cell selection and manufacturing, as all could increase efficacy.
👍️ 1
jondoeuk jondoeuk 4 주 전
ASH abstract https://ash.confex.com/ash/2024/webprogram/Paper203563.html
👍️0
jondoeuk jondoeuk 4 주 전
Q3 business update and financial results https://www.globenewswire.com/news-release/2024/11/05/2974996/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-Third-Quarter-2024-Financial-Results.html
👍️0
Monksdream Monksdream 4 주 전
CRSP 10Q 11/5
👍️0
Monksdream Monksdream 1 월 전
CRSP under $50
👍️0
jondoeuk jondoeuk 1 월 전
OT: In this Dr. Urnov, PhD, laid out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies https://www.liebertpub.com/doi/10.1089/crispr.2024.0082
👍️ 1
TechandBio TechandBio 2 월 전
CRSP will climb tremendously over the years.
SMMT went from $1.00-30.00+ this year cancer drug superior to Mercks Keytruda
ICCM company being over looked that kills cancers by freezing them 97% non recurrence rate for breast cancer after 5 years and superior data to lung cancer safe cryoblation is done in less than hour.
https://www.prnewswire.com/il/news-releases/icecure-medical-reports-positive-topline-results-from-ice3-cryoablation-breast-cancer-study-achievement-of-96-39-recurrence-free-rate-brings-company-one-step-closer-to-providing-women-a-non-surgical-alternative-to-lumpectomy-302092712.html

https://www.prnewswire.com/il/news-releases/icecure-medical-reports-positive-topline-results-from-ice3-cryoablation-breast-cancer-study-achievement-of-96-39-recurrence-free-rate-brings-company-one-step-closer-to-providing-women-a-non-surgical-alternative-to-lumpectomy-302092712.html
👍️0
Monksdream Monksdream 3 월 전
Buy range again thanks a bunch
👍️0
Monksdream Monksdream 3 월 전
Buy range again thanks a bunch
👍️0
OldAIMGuy OldAIMGuy 3 월 전
Hi MD,
Here's a little longer view:


This might also be a cyclical low here. But, most of 2024 has shown severe distribution of shares until about the last month. That, at least, seems to be flattening out.
Best wishes,
OAG
👍️0
Monksdream Monksdream 3 월 전
CRSP trend since February remains bearish
👍️0
jondoeuk jondoeuk 4 월 전
Q2 results https://finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200100452.html
👍️0
lambchops lambchops 4 월 전
Hey Monk, Hopefully you bought some shares on Friday@ Sold at 10% discount!

LC

CRISPR!!!
👍️0
Monksdream Monksdream 4 월 전
CRSP under $75
👍️0
TechandBio TechandBio 5 월 전
Crispr added some $120 Vertical debit spreads in 2026

$CRSP
👍️ 1
axelvento axelvento 6 월 전
I agree.....solid company$$$$$$$$
👍️0
Monksdream Monksdream 6 월 전
It may take some time for CRSP returns to a $200 price tag
The same could be said for hundreds of other stocks that soared during Covid mania
Since then the stock has rallied from low points
With all that money the company has to do incredible things with its biotechnology the stock isn’t going to zero
👍️ 1
axelvento axelvento 7 월 전
Strong balance sheet with approximately $2.1 billion in cash, cash equivalents, and marketable securities as of March 31, 2024

https://finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200000059.html
👍️0
jondoeuk jondoeuk 7 월 전
(OT): A new AI paper from Princeton and Stanford https://www.biorxiv.org/content/10.1101/2024.04.25.591003v2.full

CRISPR-GPT demonstrated a marked improvement in gene-editing experiments, increasing the accuracy of target gene modifications by up to 30% compared to conventional methods. In validation tests, it achieved a specificity rate exceeding 95%, with a significant reduction in off-targets. The system also reduced the time required to design and plan experiments by approximately 40%, streamlining the workflow for researchers.
👍️0
jondoeuk jondoeuk 7 월 전
Business Update and Q1 Financial Results https://uk.finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200000300.html
👍️0
jondoeuk jondoeuk 7 월 전
Highlights (plus new programs utilising in vivo gene editing) https://finance.yahoo.com/news/crispr-therapeutics-highlights-asgct-oral-110000066.html
👍️0
jondoeuk jondoeuk 7 월 전
https://www.globenewswire.com/news-release/2024/04/22/2867236/0/en/CRISPR-Therapeutics-to-Present-Oral-Presentation-at-the-American-Society-of-Gene-Cell-Therapy-ASGCT-2024-Annual-Meeting.html

EDIT is also pursuing myocilin-related glaucoma https://www.globenewswire.com/news-release/2024/04/22/2867244/0/en/Editas-Medicine-to-Present-Pre-clinical-Data-Demonstrating-Progression-of-in-vivo-Medicines-Pipeline-at-the-American-Society-of-Gene-and-Cell-Therapy-Annual-Meeting.html
👍️0
OldAIMGuy OldAIMGuy 8 월 전
StockCharts 3 year history with 20% ZigZag reversals................



CRSP seems to be suffering from lack of 'sponsorship' in that the stock has not shown "accumulation" trend along with the price rally since last year's October Low. There's been volume, but not accumulation bias.

Best wishes,
OAG
👍️0
OldAIMGuy OldAIMGuy 8 월 전
Hi MD,
CRSP is now down around 1/3 from its February high. The price is where I usually start to accumulate more shares.

Best wishes,
OAG
👍️0
Monksdream Monksdream 8 월 전
CRSP over $30
👍️0
jondoeuk jondoeuk 8 월 전
Upcoming https://uk.finance.yahoo.com/news/crispr-therapeutics-present-american-society-120000624.html
👍️0
Monksdream Monksdream 9 월 전
CRSP new 52 week high
👍️0
Monksdream Monksdream 9 월 전
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
Monksdream Monksdream 10 월 전
CRSP new 52 week high
👍️ 1
Monksdream Monksdream 10 월 전
CRSP new 52 week high
👍️ 1
jondoeuk jondoeuk 10 월 전
They entered into an investment agreement for the sale of ~$280 million of its shares to a select group of institutional investors in a registered direct offering, at $71.5 apiece. The financing is being led by EcoR1 Capital and SR One with participation from existing investors and a healthcare specialist investor https://finance.yahoo.com/news/crispr-therapeutics-announces-280-million-133000932.html
👍️0
jondoeuk jondoeuk 10 월 전
EU approval https://finance.yahoo.com/news/european-commission-approves-first-crispr-065900771.html
👍️ 1
Monksdream Monksdream 10 월 전
Didn’t tank like BLUE
Recovered


More analysis from Nanolyze

👍️0
Monksdream Monksdream 10 월 전
So there has been some discussion since my last post
More in this podcast
🌈 1 🍆 1
jondoeuk jondoeuk 10 월 전
Around two months ahead of expectations https://www.globenewswire.com/news-release/2024/01/16/2810298/0/en/CRISPR-Therapeutics-Announces-U-S-Food-and-Drug-Administration-FDA-Approval-of-CASGEVY-exagamglogene-autotemcel-for-the-Treatment-of-Transfusion-Dependent-Beta-Thalassemia.html
👍️ 1
jondoeuk jondoeuk 11 월 전
Strategic Priorities and 2024 Outlook https://finance.yahoo.com/news/crispr-therapeutics-highlights-strategic-priorities-120000043.html
👍️0
jondoeuk jondoeuk 11 월 전
Webcast link https://jpmorgan.metameetings.net/events/healthcare24/sessions/49607-crispr-therapeutics-inc/webcast/general_signin?gpu_only=true&kiosk=true
👍️ 1
jondoeuk jondoeuk 11 월 전
Upcoming https://uk.finance.yahoo.com/news/crispr-therapeutics-present-42nd-annual-133000024.html
👍️0
JJ8 JJ8 11 월 전
Good morning OAG,

Surprising and interesting. Share price sudden "jack-rabbit" moves in quick price reversals. The technical picture for today changed from positive breakout yesterday to "High Pole Warning" with sudden drop in price. Apparently the dominating group of participants seem to dictate this pace a bit unusual and different from other stocks. Yet it offers opportunity for profit once one has a good plan and strategy.

Good you have a plan and strategy for your preferred limits and ranges for your trading. Let's see how it goes. Have fun & GLTY
👍️ 1
OldAIMGuy OldAIMGuy 11 월 전
Good morning JJ8,

It needs to crest $85 or better to get me interested in reducing my share inventory. A drop to $57 will trigger an addition of 12% to share count.

I'd like to see it crest $72 and maintain that price right now.

Best wishes,
OAG
👍️0
JJ8 JJ8 11 월 전
CRSP share price Double Top Breakout today on 19-Dec-2023. Happy Holidays & GLTA
👍️0
Monksdream Monksdream 12 월 전
Oscar Wilde once observed that a cynic knows the price of everything and the value of nothing
👍️0
JJ8 JJ8 12 월 전
Windbag1014,

Thanks for your views and informative response. GLTY & GLTA
👍️0
JJ8 JJ8 12 월 전
OldAIMGuy,

Thanks for your clear and detailed response.

Your approach and strategy dealing with what Crispr T AG stock price movement over time shows, and the Crispr company activity makes good sense. More power and good luck to you.

John
👍️ 1
OldAIMGuy OldAIMGuy 12 월 전
Hi JJ8, Re: CRSP price action..........................

My guess is it's a "Sell on the News" action. This isn't the first time CRSP has shown high amplitude price change as this histogram shows:
https://schrts.co/NSfSbXYF

I think it will be important to watch the transition of this company from basically a 'research' business to one of product development and distribution. Somewhere along the way they'll have to show a profit to reward those who've invested in them. I'm fond of watching the Accumulation/Distribution activity to see what is happening with strong and weak hands holding the stock. In the mean time I plan on trimming and backfilling my position as the price moves around. I last added 12% to my position at $47.56 in August and had the opportunity to part with 10% of the holding at $69.57 a few weeks ago. The core position remains.



With each cycle of the price the portfolio builds out a bit.

Hope this helps,
OAG
👍️0
Windbag1014 Windbag1014 12 월 전
Vertex set the price of Casgevy at $2.2 million compared to $3.1 million for Bluebird’s Lyfgenia. Bluebird’s gene therapy for thalassemia, approved last year, has a list price of $2.8 million.

The therapies are also not easy to receive. Patients must spend weeks, even months, in the hospital before and after the therapy is administered. And some of the preparatory steps can cause serious side effects, including severe infections, nausea, painful mouth sores, and infertility.

https://www.statnews.com/2023/12/08/fda-approves-casgevy-crispr-based-medicine-for-treatment-of-sickle-cell-disease/#:~:text=Vertex%20set%20the%20price%20of%20Casgevy%20at%20%242.2,year%2C%20has%20a%20list%20price%20of%20%242.8%20million.

Prohibitive treatment
👍️ 1
YankeMike YankeMike 12 월 전
Probably just because the share price had run up so much before the approval, so it was kind of baked-in already and some took profits. Also, maybe because of high price tag of the treatment. Still a bright future and should trend upwards.
👍️0
JJ8 JJ8 12 월 전
The dump of Crisp shares last Friday Dec 8th after the "good" news is confusing.

The institutional ownership is 63.48%. Why this response by share owners. I assume it probably was mainly by the institutions. But why at this time? Profit taking? Haven't done a check on insiders transactions yet.

More than 17 million shares traded in one session. The average daily volume of trading happens to be about 2-3 millions of shares daily. Why the exodus a this time of "good" news.

My profits were cut in half in one session. I don't intend to sell at such times.
Actually, I buy usually. That's what I did recently after the sudden drop in Walmart share price.

Any ideas and thoughts? What's going on behind the scene? TIA

GLTA
👍️0

최근 히스토리

Delayed Upgrade Clock